Loading
Lung Non Small Cell Squamous Carcinoma / Computed Tomography / Lung Non Small Cell Carcinoma · Phase 3 Trial
ClinicalTrials.gov · August 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 randomized trial registration testing pembrolizumab plus chemotherapy versus chemotherapy alone in resected stage II–IIIB non-small cell lung cancer. The study is currently recruiting and has not yet reported results; no efficacy data are available.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lun…; age from 18 Years. Intervention: Arm B (platinum doublet, sequential pembrolizumab); Arm C (platinum doublet, combination pembrolizumab). Compared with: Arm A (platinum doublet, observation) — Active Comparator. n = 1,210. 1150 sites: United States, Guam.
This is a Phase 3 randomized trial registration testing pembrolizumab plus chemotherapy versus chemotherapy alone in resected stage II–IIIB non-small cell lung cancer. The study is currently recruiting and has not yet reported results; no efficacy data are available.
No data on efficacy, safety, or comparative effectiveness available.
Once results are available, this trial will inform whether adjuvant pembrolizumab improves disease-free survival when added to standard chemotherapy in resected NSCLC. Pending outcome reporting, no clinical recommendations can be made from this registry record.
This is a Phase 3 trial registration with no results posted; the study is still recruiting and has not yet reported outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Once results are available, this trial will inform whether adjuvant pembrolizumab improves disease-free survival when added to standard chemotherapy in resected NSCLC. Pending outcome reporting, no clinical recommendations can be made from this registry record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04267848). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1210 participants (ESTIMATED). Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8. Interventions: PROCEDURE: Biospecimen Collection; DRUG: Carboplatin; DRUG: Cisplatin; PROCEDURE: Computed Tomography; PROCEDURE: Echocardiography Test; DRUG: Gemcitabine Hydrochloride; PROCEDURE: Magnetic Resonance Imaging; OTHER: Observation Activity; DRUG: Paclitaxel; BIOLOGICAL: Pembrolizumab; DRUG: Pemetrexed Disodium; OTHER: Questionnaire Administration. Primary outcome measures: Disease free survival (DFS) , From randomization to the first of either disease recurrence or death from any cause, assessed up to 5 years after accrual completion. Brief summary: This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.